Patents by Inventor Kristian Helin
Kristian Helin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220288063Abstract: The present invention relates to lysine deficient protein kinase 1 (WNK1) inhibitors for use in treating patients with blood cancers, in particular leukemia and multiple myeloma.Type: ApplicationFiled: August 11, 2020Publication date: September 15, 2022Inventors: Kristian Helin, Karl Agger
-
Publication number: 20180271857Abstract: The invention relates to inhibitors of EZH2 for use in the treatment of cancers characterised by expression of mutated histone H3 having a mutation of amino acid number 27. The invention also relates to methods for predicting the efficacy of treatment of a cancer with an inhibitor of EZH2 by determining whether the cancer cells contain a gene encoding p16INK4A, wherein the presence of a gene encoding p16INK4A is indicative of efficacy of treatment of the cancer with an inhibitor of EZH2.Type: ApplicationFiled: December 18, 2015Publication date: September 27, 2018Applicant: University of CopenhagenInventors: Kristian HELIN, Faizaan MOHAMMAD, Jonas Westergaard HØJFELDT, Deo Prakash PANDEY, Simon WEISSMANN
-
Patent number: 9820987Abstract: The described invention provides a method of treating a patient with an epithelial cancer comprising administering a composition comprising a therapeutic amount of an inhibitor of a BTK protein and one or more chemotherapeutic agent(s) selected from the group consisting of an antimetabolite, a platinum coordination compound, an alkylating agent and a combination thereof, wherein the composition is effective to reduce one or more of tumor cell growth, tumor cell clonogenicity, tumor cell proliferation, tumor cell viability and tumor volume and the therapeutic amount of the inhibitor of a BTK protein and the one or more chemotherapeutic agent(s) exerts a synergistic effect. The described invention also provides methods of treating a chemotherapy drug-resistant cancer and sensitizing a cancer patient to chemotherapy.Type: GrantFiled: December 30, 2014Date of Patent: November 21, 2017Assignee: Bionsil S.R.L. in LiquidazioneInventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20150150899Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAI, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumor pathologies. Also described is a method for the determination of the drug resistance in tumor cells, as well as a method for the identification of tumor stem cells.Type: ApplicationFiled: October 14, 2014Publication date: June 4, 2015Applicant: BIONSIL S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20150111953Abstract: The described invention provides a method of treating a patient with an epithelial cancer comprising administering a composition comprising a therapeutic amount of an inhibitor of a BTK protein and one or more chemotherapeutic agent(s) selected from the group consisting of an antimetabolite, a platinum coordination compound, an alkylating agent and a combination thereof, wherein the composition is effective to reduce one or more of tumor cell growth, tumor cell clonogenicity, tumor cell proliferation, tumor cell viability and tumor volume and the therapeutic amount of the inhibitor of a BTK protein and the one or more chemotherapeutic agent(s) exerts a synergistic effect. The described invention also provides methods of treating a chemotherapy drug-resistant cancer and sensitizing a cancer patient to chemotherapy.Type: ApplicationFiled: December 30, 2014Publication date: April 23, 2015Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Patent number: 8889643Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAI, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumor pathologies. Also described is a method for the determination of the drug resistance in tumor cells, as well as a method for the identification of tumor stem cells.Type: GrantFiled: June 25, 2012Date of Patent: November 18, 2014Assignee: Bionsil, S.r.l.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Patent number: 8420335Abstract: The present invention provides a method of testing the ability of a test compound to bind to and optionally modulate the activity of a protein of the JMJD2 subfamily of Jumonji proteins. The method comprises incubating a test compound with a protein of the JMJD2 subfamily of Jumonji proteins, a co-factor of said protein and, optionally, a substrate for demethylation. The method of the invention can be used for screening large numbers of compounds to identify a group of compounds that are candidate compounds for clinical use for treatment of certain cancers especially prostate cancers. Other compounds that do not have activity in the screening assays can be eliminated from further consideration as candidate compounds. The method of the invention therefore has utility in the pharmaceutical industry.Type: GrantFiled: March 14, 2007Date of Patent: April 16, 2013Assignee: Kobenhavns UniversitetInventors: Paul Cloos, Karl Agger, Jesper Christensen, Klaus H. Hansen, Kristian Helin
-
Publication number: 20130041014Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAl, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.Type: ApplicationFiled: June 25, 2012Publication date: February 14, 2013Applicant: BIONSIL S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20130041013Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.Type: ApplicationFiled: June 25, 2012Publication date: February 14, 2013Applicant: BIONSIL S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20130041012Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAI, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.Type: ApplicationFiled: June 25, 2012Publication date: February 14, 2013Applicant: BIONSIL S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Patent number: 8232085Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERN1, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumor pathologies. Also described is a method for the determination of the drug resistance in tumor cells, as well as a method for the identification of tumor stem cells.Type: GrantFiled: March 14, 2008Date of Patent: July 31, 2012Assignee: Bionsil S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20100081704Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERN1, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.Type: ApplicationFiled: March 14, 2008Publication date: April 1, 2010Applicant: UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCAInventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20090162945Abstract: The present invention provides a method of testing the ability of a test compound to bind to and optionally modulate the activity of a protein of the JMJD2 subfamily of Jumonji proteins. The method comprises incubating a test compound with a protein of the JMJD2 subfamily of Jumonji proteins, a co-factor of said protein and, optionally, a substrate for demethylation. The method of the invention can be used for screening large numbers of compounds to identify a group of compounds that are candidate compounds for clinical use for treatment of certain cancers especially prostate cancers. Other compounds that do not have activity in the screening assays can be eliminated from further consideration as candidate compounds. The method of the invention therefore has utility in the pharmaceutical industry.Type: ApplicationFiled: March 14, 2007Publication date: June 25, 2009Inventors: Paul Cloos, Karl Agger, Jesper Christensen, Klaus H. Hansen, Kristian Helin